vs
Side-by-side financial comparison of Amgen (AMGN) and NATURAL HEALTH TRENDS CORP (NHTC). Click either name above to swap in a different company.
Amgen is the larger business by last-quarter revenue ($9.9B vs $9.7M, roughly 1012.0× NATURAL HEALTH TRENDS CORP). Amgen runs the higher net margin — 13.5% vs -6.0%, a 19.5% gap on every dollar of revenue. On growth, Amgen posted the faster year-over-year revenue change (8.6% vs -10.1%). Amgen produced more free cash flow last quarter ($961.0M vs $-964.0K). Over the past eight quarters, Amgen's revenue compounded faster (15.1% CAGR vs -5.6%).
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
Sword Health is a digital health company that develops physical therapy programs for musculoskeletal (MSK) conditions, pelvic health, and injury prevention. The company was founded in 2015 in Portugal by Virgílio Bento and Márcio Colunas. Its services include digital physical therapy with artificial intelligence (AI) integrated into the care model. As of 2024, Sword Health operates internationally, with offices in the United States, Ireland, and Portugal. The company has been valued at $3 bil...
AMGN vs NHTC — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $9.9B | $9.7M |
| Net Profit | $1.3B | $-588.0K |
| Gross Margin | 69.8% | 72.9% |
| Operating Margin | 27.6% | -6.5% |
| Net Margin | 13.5% | -6.0% |
| Revenue YoY | 8.6% | -10.1% |
| Net Profit YoY | 112.6% | -434.1% |
| EPS (diluted) | $2.45 | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.9B | $9.7M | ||
| Q3 25 | $9.6B | $9.5M | ||
| Q2 25 | $9.2B | $9.8M | ||
| Q1 25 | $8.1B | $10.7M | ||
| Q4 24 | $9.1B | $10.8M | ||
| Q3 24 | $8.5B | $10.7M | ||
| Q2 24 | $8.4B | $10.5M | ||
| Q1 24 | $7.4B | $11.0M |
| Q4 25 | $1.3B | $-588.0K | ||
| Q3 25 | $3.2B | $-431.0K | ||
| Q2 25 | $1.4B | $15.0K | ||
| Q1 25 | $1.7B | $122.0K | ||
| Q4 24 | $627.0M | $176.0K | ||
| Q3 24 | $2.8B | $35.0K | ||
| Q2 24 | $746.0M | $173.0K | ||
| Q1 24 | $-113.0M | $188.0K |
| Q4 25 | 69.8% | 72.9% | ||
| Q3 25 | 67.8% | 73.7% | ||
| Q2 25 | 67.2% | 73.9% | ||
| Q1 25 | 63.6% | 73.6% | ||
| Q4 24 | 65.7% | 74.2% | ||
| Q3 24 | 61.1% | 74.1% | ||
| Q2 24 | 61.4% | 74.2% | ||
| Q1 24 | 57.0% | 73.4% |
| Q4 25 | 27.6% | -6.5% | ||
| Q3 25 | 26.4% | -5.2% | ||
| Q2 25 | 28.9% | -3.4% | ||
| Q1 25 | 14.5% | -3.2% | ||
| Q4 24 | 25.4% | -3.9% | ||
| Q3 24 | 24.1% | -2.6% | ||
| Q2 24 | 22.8% | -2.3% | ||
| Q1 24 | 13.3% | -3.3% |
| Q4 25 | 13.5% | -6.0% | ||
| Q3 25 | 33.7% | -4.5% | ||
| Q2 25 | 15.6% | 0.2% | ||
| Q1 25 | 21.2% | 1.1% | ||
| Q4 24 | 6.9% | 1.6% | ||
| Q3 24 | 33.3% | 0.3% | ||
| Q2 24 | 8.9% | 1.7% | ||
| Q1 24 | -1.5% | 1.7% |
| Q4 25 | $2.45 | $-0.05 | ||
| Q3 25 | $5.93 | $-0.04 | ||
| Q2 25 | $2.65 | $0.00 | ||
| Q1 25 | $3.20 | $0.01 | ||
| Q4 24 | $1.17 | $0.01 | ||
| Q3 24 | $5.22 | $0.00 | ||
| Q2 24 | $1.38 | $0.02 | ||
| Q1 24 | $-0.21 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.1B | $28.9M |
| Total DebtLower is stronger | $54.6B | — |
| Stockholders' EquityBook value | $8.7B | $23.4M |
| Total Assets | $90.6B | $38.4M |
| Debt / EquityLower = less leverage | 6.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.1B | $28.9M | ||
| Q3 25 | $9.4B | $32.0M | ||
| Q2 25 | $8.0B | $34.2M | ||
| Q1 25 | $8.8B | $41.9M | ||
| Q4 24 | $12.0B | $43.9M | ||
| Q3 24 | $9.0B | $46.3M | ||
| Q2 24 | $9.3B | $48.7M | ||
| Q1 24 | $9.7B | $54.4M |
| Q4 25 | $54.6B | — | ||
| Q3 25 | $54.6B | — | ||
| Q2 25 | $56.2B | — | ||
| Q1 25 | $57.4B | — | ||
| Q4 24 | $60.1B | — | ||
| Q3 24 | $60.4B | — | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
| Q4 25 | $8.7B | $23.4M | ||
| Q3 25 | $9.6B | $26.1M | ||
| Q2 25 | $7.4B | $28.9M | ||
| Q1 25 | $6.2B | $30.9M | ||
| Q4 24 | $5.9B | $32.9M | ||
| Q3 24 | $7.5B | $35.3M | ||
| Q2 24 | $5.9B | $37.3M | ||
| Q1 24 | $5.0B | $39.4M |
| Q4 25 | $90.6B | $38.4M | ||
| Q3 25 | $90.1B | $42.3M | ||
| Q2 25 | $87.9B | $45.2M | ||
| Q1 25 | $89.4B | $53.2M | ||
| Q4 24 | $91.8B | $55.4M | ||
| Q3 24 | $90.9B | $58.3M | ||
| Q2 24 | $90.9B | $61.5M | ||
| Q1 24 | $93.0B | $67.6M |
| Q4 25 | 6.31× | — | ||
| Q3 25 | 5.67× | — | ||
| Q2 25 | 7.57× | — | ||
| Q1 25 | 9.24× | — | ||
| Q4 24 | 10.23× | — | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.6B | $-959.0K |
| Free Cash FlowOCF − Capex | $961.0M | $-964.0K |
| FCF MarginFCF / Revenue | 9.7% | -9.9% |
| Capex IntensityCapex / Revenue | 6.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.20× | — |
| TTM Free Cash FlowTrailing 4 quarters | $8.1B | $-6.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $-959.0K | ||
| Q3 25 | $4.7B | $113.0K | ||
| Q2 25 | $2.3B | $-5.6M | ||
| Q1 25 | $1.4B | $484.0K | ||
| Q4 24 | $4.8B | $88.0K | ||
| Q3 24 | $3.6B | $-436.0K | ||
| Q2 24 | $2.5B | $-3.6M | ||
| Q1 24 | $689.0M | $549.0K |
| Q4 25 | $961.0M | $-964.0K | ||
| Q3 25 | $4.2B | $70.0K | ||
| Q2 25 | $1.9B | $-5.6M | ||
| Q1 25 | $980.0M | $468.0K | ||
| Q4 24 | $4.4B | $68.0K | ||
| Q3 24 | $3.3B | $-443.0K | ||
| Q2 24 | $2.2B | $-3.6M | ||
| Q1 24 | $459.0M | $538.0K |
| Q4 25 | 9.7% | -9.9% | ||
| Q3 25 | 44.4% | 0.7% | ||
| Q2 25 | 20.8% | -57.5% | ||
| Q1 25 | 12.0% | 4.4% | ||
| Q4 24 | 48.4% | 0.6% | ||
| Q3 24 | 39.0% | -4.1% | ||
| Q2 24 | 26.5% | -34.2% | ||
| Q1 24 | 6.2% | 4.9% |
| Q4 25 | 6.5% | 0.1% | ||
| Q3 25 | 4.6% | 0.5% | ||
| Q2 25 | 4.0% | 0.0% | ||
| Q1 25 | 5.0% | 0.1% | ||
| Q4 24 | 4.1% | 0.2% | ||
| Q3 24 | 3.0% | 0.1% | ||
| Q2 24 | 2.8% | 0.2% | ||
| Q1 24 | 3.1% | 0.1% |
| Q4 25 | 1.20× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.59× | -375.67× | ||
| Q1 25 | 0.80× | 3.97× | ||
| Q4 24 | 7.61× | 0.50× | ||
| Q3 24 | 1.26× | -12.46× | ||
| Q2 24 | 3.30× | -20.62× | ||
| Q1 24 | — | 2.92× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
NHTC
Segment breakdown not available.
